Negotiations over key World Zionist Organization posts stall after surprise bid to appoint Yair Netanyahu to a senior role, prompting outrage and extended talks.
Large-cap stocks face varied financial risks and opportunities, with some showing strong growth and profitability, while others struggle with declining sales and profitability.
Novartis to acquire Avidity Biosciences for $12 billion, bolstering its neuroscience pipeline with late-stage programs.
Negotiations over key World Zionist Organization posts stall after surprise bid to appoint Yair Netanyahu to a senior role, prompting outrage and extended talks.
Large-cap stocks face varied financial risks and opportunities, with some showing strong growth and profitability, while others struggle with declining sales and profitability.
Novartis to acquire Avidity Biosciences for $12 billion, bolstering its neuroscience pipeline with late-stage programs.